Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2.
Armstrong
P W
PW
University of Alberta, Edmonton, Alberta, Canada. paul.armstrong@ualberta.ca
Collen
D
D
D000367:Age Factors; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D000075202:Contraindications; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced / Q000517:prevention & control; D008297:Male; D009203:Myocardial Infarction / Q000628:therapy*; D015425:Myocardial Reperfusion / Q000379:methods* / Q000639:trends; D010960:Plasminogen Activators / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D012737:Sex Factors; D013917:Thrombin / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D010960:Plasminogen Activators; D013917:Thrombin